Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.64 |
| ▸ | UBE2M | P61081 | 5/20 | 0.62 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628043 | 0.90 | HIF1A (0.69) | HIF1AEPAS1KMT2AEPHX2RAB9A | |
| SCHEMBL18658209 | 0.90 | EGFR (0.71) | KMT2AEPHX2UBE2MDCUN1D1EGFR | |
| SCHEMBL18387541 | 0.85 | EGFR (0.86) | EGFRKDR | |
| SCHEMBL16628039 | 0.82 | MAPK14 (0.71) | HIF1AEPAS1KMT2AKDRLMNA | |
| SCHEMBL26823043 | 0.81 | THRB (0.54) | HIF1AEPAS1THRBKMT2AEPHX2 | |
| SCHEMBL18657815 | 0.81 | EPHX2 (0.80) | KMT2AEPHX2UBE2MDCUN1D1LMNA | |
| SCHEMBL4921397 | 0.80 | HIF1A (0.55) | HIF1AEPAS1KMT2ALMNARAB9A | |
| SCHEMBL5175836 | 0.78 | HIF1A (0.53) | HIF1AEPAS1KMT2AEPHX2LMNA | |
| SCHEMBL4915419 | 0.78 | NPC1 (0.78) | HIF1AEPAS1KMT2AEPHX2LMNA | |
| SCHEMBL4262607 | 0.78 | EPHX2 (1.00) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2017049295-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | HIF1A 2864/4885EPAS1 1465/4885THRB 4604/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | HIF1A 2864/4885EPAS1 1465/4885THRB 4604/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | HIF1A 2864/4885EPAS1 1465/4885THRB 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.